Allison DeAngelis
Reporter at STAT
Reporter covering biopharma startups and venture capital at @statnews. Formerly @thisisinsider and @bosbizjournal.
Articles
-
2 days ago |
statnews.com | Allison DeAngelis
Biotech investment firm RA Capital has laid off staff at its internal startup incubator, STAT has learned, highlighting the instability among VCs as the biotech industry struggles to right itself. The cuts hit RA Ventures, or Raven, an incubator that creates and supports biotech startups. The Raven team has launched several biotechs over the years, including Aliada Therapeutics and Mariana Oncology, both of which were acquired last year.
-
6 days ago |
statnews.com | Allison DeAngelis |Adam Feuerstein
What does the appointment of Vinay Prasad as the head of biologic drug evaluation mean for biotechs? Is his fiery public persona suited for government service? We discuss these and other burning questions on a new episode of “The Readout LOUD,” STAT’s biotech podcast. Matt Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health agencies. He and Adam debate just how disruptive Prasad’s tenure could be.
-
1 week ago |
statnews.com | Allison DeAngelis
In January, San Francisco’s Union Square was bustling with hordes of drug developers and investors, pounding the pavement on their way from meeting to meeting. But Rohan Ganesh, an investor at the VC firm Obvious Ventures, wasn’t among them. He only agreed to hear one company’s pitch during this year’s J.P. Morgan Healthcare Conference. The meeting was with a startup created by Flatiron Health veterans Josh Haimson and Ben Birnbaum.
-
1 week ago |
statnews.com | Adam Feuerstein |Allison DeAngelis |Elaine Chen
On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong drug launches, and Eli Lilly’s PBM problem. The first 100 days of the Trump administration have had a profound impact on federal health agencies, medical research, health policy and the biotech and pharmaceuticals industries.
-
2 weeks ago |
statnews.com | Allison DeAngelis |Jason Mast |Elaine Chen
Health and Human Services Secretary Robert F. Kennedy Jr. has railed against what he sees as a “revolving door” between workers at drug companies and the Food and Drug Administration. But his department’s actions now seem to be causing that door to spin ever faster. Scores of FDA employees are searching for an exit from an agency in turmoil, particularly staff members tasked with reviewing drug applications, according to interviews with former employees and industry recruiters.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 5K
- Tweets
- 4K
- DMs Open
- Yes
RT @statnews: What does the appointment of Vinay Prasad as the head of biologic drug evaluation mean for biotechs? Is his fiery public pers…
RT @statnews: The European Commission unveiled a $565 million package to retain and attract scientists, as other countries try to leverage…
Biopharma executives have remained largely quiet while the Trump admin has upended scientific organizations. But @JonathanWosen reports from a Stanford event that there are signs that life science veterans are beginning to rethink silence as a strategy. https://t.co/7Ee1erHaq1
